Blueprint Medicines to Present at Upcoming Investor Conferences in August
Canaccord Genuity 36th Annual Growth Conference inBoston, MA onWednesday, August 10, 2016 at2:00 p.m. ET .Wedbush PacGrow Healthcare Conference inNew York, NY onTuesday, August 16, 2016 at9:10 a.m. ET .
A live webcast of each presentation will be available by visiting the Investors section of
About
Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.
Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-august-300306154.html
SOURCE
Investor Relations: Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, kwilliams@blueprintmedicines.com; Media Relations: Rachel Hutman, W2O Group, 301-801-5540, rhutman@wcgworld.com